Endo Pharma (ENDP) Extends Period of Tender Offer for Shares of Indevus (IDEV)
More News related to ENDP
- Endo Pharma (ENDP) Announces Settlement with LecTec Over Outstanding Patent Litigation
- Endo Pharmaceuticals and LecTec Settle Patent Dispute
- Endo Pharma (ENDP) Posts Q3 EPS of $0.63, Misses By 1c; Guides
- Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
More News related to IDEV
- Endo Pharma (ENDP) Extends Period of Tender Offer for Shares of Indevus (IDEV)
- Indevus Pharma (IDEV) Announces NIH-Sponsored Study on PRO 2000 Shows Promise in HIV Prevention
- JMP Downgrades Indevus Pharma (IDEV) to Market Perform
- UBS Downgrades Indevus Pharmaceuticals (IDEV) to Neutral
- Unusual 11 Mid-Day Movers 1/6: IDEV, TXCO, ARM, ALD Higher; VDSI, CTDC, SMCI, ENDP Lower
Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it has extended the subsequent offering period of the tender offer by its wholly owned subsidiary, BTB Purchaser Inc., for all of the outstanding shares of common stock of Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV). The subsequent offering period will now expire at 5:00 p.m. New York City time on Friday, March 13, 2009.
Related Categories
Mergers and AcquisitionsStocks Mentioned
-0.13
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
